Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria

Clinical Infectious Diseases

Volumn 57, Issue 12, 2013, Pages

  Hawkins, Claudia ^a   Agbaji, Oche ^b   Ugoagwu, Placid ^b   Thio, Chloe L ^c   Auwal, Muazu M ^b   Ani, Charles ^b   Okafo, Chinedum ^b   Wallender, Erika ^d   Murphy, Robert L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF JOS   (Nigeria)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Africa; HBV; HIV; liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DNA VIRUS; ELASTOGRAPHY; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NIGERIA; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; TRANSIENT ELASTOGRAPHY; VIROLOGY;

AFRICA; HBV; HIV; LIVER FIBROSIS;

ADULT; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS B; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; NIGERIA; RISK FACTORS;

EID: 84890032612     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit564     Document Type: Article

References (12)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362:2089-94
2. Miailhes P, Pradat P, Chevallier M, et al. Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients. J Viral Hepat 2011; 18:61-9
3. Federal Ministry of Health. National guidelines for HIV and AIDS treatment and care in adolescents and adults. Abuja, Nigeria, 2010. Available at: Http://www.who.int/hiv/pub/guidelines/nigeria-art.pdf. Accessed 3 January 2013
4. Stabinski L, Reynolds SJ, Ocama P, et al. High prevalence of liver fibrosis associated with HIV infection: A study in rural Rakai, Uganda. Antivir Ther 2011; 16:405-11
5. Sellier P, Schnepf N, Jarrin I, et al. Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol 2010; 47:13-7
6. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-6
7. Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIVHBV- coinfected patients: Clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther 2010; 15:963-74
8. Price JC, Seaberg EC, Badri S, Witt MD, D'Acunto K, Thio CL. HIV monoinfection is associated with increased aspartate aminotransferaseto- platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis 2012; 205:1005-13
9. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: The REVEAL-HBV study. Clin Liver Dis 2007; 11:797-816, viii
10. Holoman J, Glasa J. EASL clinical practice guidelines. J Hepatol 2009; 51:821-2
11. Roca B, Resino E, Torres V, Herrero E, Penades M. Interobserver discrepancy in liver fibrosis using transient elastography. J Viral Hepat 2012; 19:711-5
12. Kim SU, Ahn SH, Park JY, et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol 2009; 43:267-71